SurgLine International, Inc. (SGLN) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SurgLine International, Inc. (SGLN) trades at $0.0001. SurgLine International, Inc. distributes a broad range of medical and surgical products under its proprietary "Surg" brand to diverse healthcare providers. Sector: Industrials.
Price as of Jul 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for SGLN: SGLN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SGLN against Industrials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SGLN: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →SurgLine International, Inc. (SGLN) Industrial Operations Profile
SurgLine International, Inc. is a distributor of medical and surgical products, offering a wide array of instruments, power tools, and disposables under its proprietary "Surg" brand to a diverse healthcare client base. Operating within the Industrials sector on the OTC Other tier, the company navigates the medical device market with a focus on specialized surgical solutions.
What Is the Investment Thesis for SGLN?
SurgLine International, Inc. operates as a distributor of medical and surgical products, leveraging its proprietary "Surg" brand to supply a diverse clientele including hospitals, surgery centers, and independent practitioners. The company's gross margin of 34.4% indicates a healthy markup on its distributed products. A key value driver for SurgLine is the ongoing demand within the broader medical device sector, which is supported by an aging global population and advancements in surgical procedures, potentially driving consistent need for its specialized instruments and disposables. However, the investment thesis must acknowledge significant challenges. SurgLine currently reports a deeply negative profit margin of -2408.9% and a market capitalization of $0.00B, indicating substantial financial distress or limited market activity. Its high beta of 7.28 suggests extreme price volatility, which, combined with its OTC Other tier listing, points to a higher risk profile, including potential liquidity challenges and limited public disclosure. Future growth catalysts would likely involve a substantial turnaround in profitability, successful expansion of its product lines, or significant market penetration within its existing client base. Investors would need to monitor any improvements in financial health and operational transparency closely for a re-evaluation of its investment profile.
Based on FMP financials and quantitative analysis
SGLN Key Highlights
- Market Capitalization: $0.00B, indicating a micro-cap status or extremely limited market valuation.
- Gross Margin: 34.4%, reflecting a solid profit percentage on product sales before operating expenses.
- Profit Margin: -2408.9%, highlighting significant unprofitability from overall operations.
- Beta: 7.28, suggesting extremely high volatility relative to the broader market.
- Dividend Yield: None, as the company does not currently distribute dividends to shareholders.
Who Are SGLN's Competitors?
SGLN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NXU Nxu, Inc. | $2.45 | +100.00% | $5.42M | 60 |
| ARTGF Airthings ASA | $0.04 | -91.82% | $8.10M | 49 |
| DFEL China TMK Battery Systems Inc. | $1.70 | +0.00% | $25.6M | 63 |
| DCFC Tritium DCFC Limited | $3.64 | +0.00% | 56 | |
| ZOOZ ZOOZ Strategy Ltd. | $4.97 | -0.40% | $40.3M | 54 |
| NVX Novonix Limited | $0.40 | -2.39% | $59.8M | 59 |
| TNTLF Tantalus Systems Holding Inc. | $1.19 | -6.84% | $60.6M | 49 |
| ILIKF Ilika plc | $0.38 | +3.81% | $63.9M | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SGLN's Key Strengths?
- Diverse and extensive catalog of medical and surgical products under a proprietary "Surg" brand.
- Broad client base spanning hospitals, ASCs, independent practitioners, and urgent care facilities.
- Specialization in high-demand areas like spinal systems and emergency implant removal devices.
- Positive gross margin of 34.4% on product sales.
What Are SGLN's Weaknesses?
- Significantly negative profit margin of -2408.9%, indicating substantial operational losses.
- OTC Other tier listing, implying potential liquidity issues and limited market transparency.
- Market capitalization of $0.00B, suggesting extremely low valuation or market activity.
- "Unknown" disclosure status on the OTC market, limiting investor access to financial information.
What Could Drive SGLN Stock Higher?
- Sustained demand for medical and surgical products driven by an aging population and increasing healthcare needs.
- Potential for new product introductions or significant expansions of the "Surg" brand product catalog.
- Expansion of distribution agreements or increased market penetration within its existing diverse client base.
- Any future improvements in financial reporting and transparency that could elevate its OTC market tier.
What Are the Key Risks for SGLN?
- Deeply negative profit margin of -2408.9% indicating severe operational unprofitability.
- Significant liquidity risk and potential difficulty in trading shares due to its OTC Other listing and $0.00B market capitalization.
- "Unknown" disclosure status, severely limiting investor access to crucial financial and operational information.
- Intense competition within the medical device distribution sector from larger, more established players.
- Regulatory changes or increased scrutiny in the medical device industry affecting product compliance or distribution.
What Are the Growth Opportunities for SGLN?
- **Expanding Product Portfolio for Niche Surgical Needs**: SurgLine's extensive catalog, including specialized tools for hand, foot, hip, small fragment, and spinal surgeries, presents a significant growth avenue. By continually researching and introducing new, advanced surgical instruments and systems under its "Surg" brand, the company can capture emerging market segments. The global orthopedic devices market, for instance, is projected to grow, driven by an aging population and increasing prevalence of musculoskeletal disorders. Focusing on high-demand, high-margin specialized instruments like advanced pedicle screw systems or next-generation endoscopes could enhance revenue and market share.
- **Deepening Penetration within Ambulatory Surgery Centers (ASCs)**: Ambulatory Surgery Centers are a rapidly growing segment of the healthcare market, favored for their cost-effectiveness and efficiency for outpatient procedures. SurgLine's current client base already includes ASCs, indicating an established channel. By intensifying sales and marketing efforts specifically tailored to the needs of ASCs, offering competitive pricing, and ensuring robust supply chain reliability, SurgLine can significantly increase its sales volume. The shift towards outpatient care is an ongoing trend, making ASCs a fertile ground for sustained growth in demand for surgical disposables and instruments.
- **Leveraging the "Surg" Proprietary Brand for Market Recognition**: The company's commitment to its proprietary "Surg" brand across its diverse product lines, from basic instruments to complex spinal systems, offers a unique opportunity. By investing in brand building, quality assurance certifications, and direct marketing to healthcare professionals, SurgLine can differentiate its offerings from generic alternatives. A strong brand reputation can foster customer loyalty, command premium pricing, and facilitate easier entry into new markets or product categories. This strategy aims to capitalize on the trust and recognition associated with a consistent, quality-focused brand in the medical field.
- **Targeting the Growing Dental and Urgent Care Markets**: SurgLine already supplies dentists and urgent care facilities, indicating existing market access. These segments represent distinct growth opportunities. The dental equipment market continues to expand due to increasing awareness of oral health and advancements in dental procedures. Similarly, urgent care facilities are proliferating as a convenient alternative for immediate, non-emergency medical needs, requiring a steady supply of medical disposables and basic instruments. By developing targeted product bundles and sales strategies for these specific client types, SurgLine can expand its market footprint beyond traditional hospital settings.
- **Expanding into Emergency and Implant Extraction Device Markets**: The provision of essential emergency removal devices for broken screws and implant extraction highlights a critical, often overlooked, niche. As the volume of implant surgeries increases globally, so does the potential need for revision surgeries and implant removal. SurgLine can expand its offerings in this specialized area, developing more advanced or comprehensive removal kits. This segment benefits from a non-discretionary demand, as these devices are crucial for patient safety and surgical outcomes, providing a stable and potentially high-margin revenue stream within the broader surgical equipment market.
What Opportunities Does SGLN Have?
- Growing global demand for medical devices driven by an aging population and advancements in healthcare.
- Expansion into new specialized product lines or enhancement of existing "Surg" brand offerings.
- Increased penetration within the rapidly growing ambulatory surgery center (ASC) market.
- Leveraging existing client relationships to cross-sell and expand product utilization.
What Threats Does SGLN Face?
- Intense competition from larger, more established medical device manufacturers and distributors.
- Regulatory changes in the medical device industry affecting product approvals or distribution.
- Economic downturns impacting healthcare spending and demand for elective procedures.
- Challenges associated with OTC trading, including difficulty raising capital and maintaining investor interest.
What Are SGLN's Competitive Advantages?
- Proprietary "Surg" brand, establishing a recognized label for its product offerings.
- Extensive and diverse product catalog, covering a wide range of surgical specialties and general medical needs.
- Broad and established client base across various healthcare provider types, fostering recurring relationships.
- Specialization in critical areas like spinal applications and emergency implant removal devices addresses specific market demands.
What Does SGLN Do?
SurgLine International, Inc. operates as a dedicated provider and distributor of an extensive portfolio of medical and surgical products, catering to a broad spectrum of healthcare entities. The company's origins trace back to October 2011 when it was established under its current name, evolving from its previous identity as China Nuvo Solar Energy, Inc. Headquartered in Newport Beach, California, SurgLine has since carved a niche in the medical device sector by supplying essential tools and disposables to acute care hospitals, ambulatory surgery centers, independent physicians, dentists, urgent care facilities, and insurance entities. Its comprehensive product catalog is a cornerstone of its market position, encompassing a wide selection of surgical instruments. This includes common items such as scissors and forceps, alongside highly specialized tools like basket punches, reamers, and pulse lavage systems. SurgLine also provides complete surgical sets tailored for specific procedures, including those involving the hand and foot, as well as hip and small fragment surgeries. For spinal applications, the company offers advanced systems such as ALIF, anterior cervical plates, PLIF, TLIF, cervical PEEK IBFDs, and various pedicle screw systems, demonstrating its commitment to specialized surgical support. Beyond instruments, SurgLine furnishes robust drill systems and power tools, featuring both cordless and pneumatic drills, complete with associated components like chucks, sleeves, saws, hoes, chargers, and batteries. The company further addresses critical needs with emergency removal devices for broken screws and implant extraction, a variety of endoscopes, specialized surgical burs and blades, and a broad range of medical, surgical, and dental disposables. All these offerings are consolidated under the company's proprietary "Surg" brand, which signifies its own label and quality assurance. This extensive and specialized product range, coupled with a diverse client base, positions SurgLine as a key supplier in the medical and surgical equipment distribution landscape.
What Products and Services Does SGLN Offer?
- Distributes a diverse range of medical and surgical products.
- Supplies common surgical instruments like scissors and forceps.
- Provides specialized surgical tools such as basket punches, reamers, and pulse lavage systems.
- Offers complete surgical sets for hand, foot, hip, and small fragment procedures.
- Furnishes comprehensive spinal application systems, including ALIF, cervical plates, and pedicle screw systems.
- Provides robust drill systems and power tools, both cordless and pneumatic, with accessories.
- Supplies emergency removal devices for broken screws and implant extraction.
- Offers various endoscopes, specialized surgical burs, blades, and medical/surgical/dental disposables.
- All products are offered under the proprietary "Surg" brand.
How Does SGLN Make Money?
- Sources and distributes a wide array of medical and surgical equipment and disposables.
- Generates revenue through direct sales of products under its proprietary "Surg" brand to healthcare providers.
- Focuses on a diverse client base including hospitals, ambulatory surgery centers, and independent practitioners.
- Maintains a broad product catalog to meet varied surgical and medical needs across multiple specialties.
What Industry Does SGLN Operate In?
SurgLine International, Inc. is positioned within the Electrical Equipment & Parts industry, specifically focusing on the distribution of medical and surgical equipment. This sector is characterized by a constant demand driven by healthcare needs, an aging population, and technological advancements in medical procedures. The overall medical device market is robust, with continuous innovation in surgical instruments, diagnostic tools, and disposables. SurgLine operates as a distributor, supplying a wide array of products under its proprietary "Surg" brand to various healthcare providers. Its competitive landscape includes both larger, established medical device manufacturers and other specialized distributors. While the market offers inherent demand, SurgLine's positioning as an OTC-listed entity with limited public information suggests it operates in a more niche or less transparent segment compared to major industry players. Success in this environment often hinges on product quality, supply chain efficiency, and strong client relationships.
Who Are SGLN's Key Customers?
- Acute care hospitals
- Ambulatory surgery centers (ASCs)
- Independent physicians and dentists
- Urgent care facilities
- Insurance entities
ROE 172%Key Financial Metrics
Return on equity for SurgLine International, Inc. stands at 171.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -62.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 4/9Financial Health
SurgLine International, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
SGLN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diverse and extensive catalog of medical and surgical products under a proprietary "Surg" brand.
- Broad client base spanning hospitals, ASCs, independent practitioners, and urgent care facilities.
- Specialization in high-demand areas like spinal systems and emergency implant removal devices.
- Positive gross margin of 34.4% on product sales.
Bear Case
- Significantly negative profit margin of -2408.9%, indicating substantial operational losses.
- OTC Other tier listing, implying potential liquidity issues and limited market transparency.
- Market capitalization of $0.00B, suggesting extremely low valuation or market activity.
- "Unknown" disclosure status on the OTC market, limiting investor access to financial information.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SGLN Latest News
No recent news available for SGLN.
SGLN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SGLN.
Price Targets
Wall Street price target analysis for SGLN.
SGLN MoonshotScore
What does this score mean?
The MoonshotScore rates SGLN 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Thomas G. Toland
CEO
Thomas G. Toland serves as the Chief Executive Officer of SurgLine International, Inc. Specific details regarding Mr. Toland's extensive career history, educational background, and previous executive roles prior to his tenure at SurgLine International, Inc. are not publicly available within the provided source data. His professional journey and the experiences that shaped his leadership in the medical and surgical product distribution sector remain undisclosed in the current information.
Track Record: Under Thomas G. Toland's leadership, SurgLine International, Inc. has continued its operations as a distributor of medical and surgical products, maintaining its proprietary "Surg" brand and serving a diverse range of healthcare providers. Key achievements or strategic decisions directly attributable to his tenure, such as significant product launches, market expansions, or specific financial milestones, are not detailed in the provided information.
SGLN OTC Market Information
SurgLine International, Inc. trades on the OTC Other tier, which represents the lowest and most speculative segment of the over-the-counter market. Unlike companies listed on major exchanges like the NYSE or NASDAQ, which adhere to stringent listing requirements regarding financial health, market capitalization, and corporate governance, OTC Other companies have minimal or no disclosure obligations. This tier typically includes companies that do not meet the standards for OTCQX, OTCQB, or Pink Current Information tiers, often due to a lack of current financial reporting. Consequently, investing in OTC Other stocks carries significantly higher risks due to limited transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited Information & Transparency: "Unknown" disclosure status severely restricts access to financial statements, operational updates, and material events, making informed decision-making challenging.
- Extreme Price Volatility: A beta of 7.28 indicates exceptionally high price fluctuations, exacerbated by low liquidity and speculative trading.
- Liquidity Challenges: Very low trading volumes and wide bid-ask spreads can make it difficult to buy or sell shares at desired prices, leading to potential capital lock-up.
- Regulatory Scrutiny & Enforcement: Companies on the OTC Other tier face less regulatory oversight, increasing the risk of fraudulent activities or misrepresentation.
- Difficulty Raising Capital: The lack of transparency and low market confidence often makes it challenging for OTC Other companies to attract institutional investment or raise capital for growth.
- Verify any available financial statements, even if unaudited or outdated, for signs of revenue and asset base.
- Research any public announcements or news releases from the company, however infrequent, for operational updates.
- Investigate the company's management team beyond the CEO for any public records or professional history.
- Assess the actual trading volume and bid-ask spread to understand potential liquidity constraints.
- Examine any regulatory filings, even if minimal, with the SEC or state authorities.
- Seek independent verification of the company's business operations, product claims, and client base.
- Understand the legal and regulatory framework governing OTC Other securities.
- Clear and consistent description of its business operations as a medical and surgical product distributor.
- Identification of a proprietary "Surg" brand for its product offerings.
- Stated headquarters location in Newport Beach, California.
- Named CEO, Thomas G. Toland, indicating a formal leadership structure.
- Existence of a defined client base including various healthcare providers.
Common Questions About SGLN (Industrials)
What does SurgLine International, Inc. do?
SurgLine International, Inc. functions as a distributor and provider of a wide array of medical and surgical products. Its extensive catalog includes common surgical instruments like scissors and forceps, specialized tools such as basket punches and reamers, and complete surgical sets for procedures involving the hand, foot, hips, and spine.
What are the key financial metrics investors watch for SGLN?
For SurgLine International, Inc., investors closely monitor several key financial metrics, particularly given its OTC listing and current financial profile. The gross margin of 34.4% is important as it indicates the profitability of its core product sales. However, the deeply negative profit margin of -2408.9% is a critical metric, highlighting significant operational losses that require close attention.
What are the main risks for SGLN?
SurgLine International, Inc. faces several significant risks, primarily stemming from its financial performance and market listing. The company's deeply negative profit margin of -2408.9% indicates substantial unprofitability, posing a fundamental challenge to its long-term viability. As an OTC Other tier stock with an "Unknown" disclosure status, SGLN carries considerable risks related to transparency and liquidity.
What are the key factors to evaluate for SGLN?
Evaluate SGLN on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does SGLN data refresh on this page?
SGLN's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SGLN's recent stock price performance?
SurgLine International, Inc. (SGLN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse and extensive catalog of medical and surgical products under a proprietary "Surg" brand. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SGLN overvalued or undervalued right now?
SurgLine International, Inc. (SGLN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SGLN before investing?
Before investing in SurgLine International, Inc. (SGLN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on provided source data, which indicates limited public disclosure for SurgLine International, Inc. (SGLN).
- Financial metrics like Market Cap and Profit Margin suggest significant challenges or limited market activity, which could impact the accuracy of broader market comparisons.
- The 'Unknown' disclosure status for its OTC listing means comprehensive financial and operational details are not readily available, impacting the depth of analysis.